Skip to content

Trial Summary

This is an open-label, multicenter, extension study to evaluate the long-term safety of tislelizumab or pamiparib given either as monotherapy or in combination with each other or with other agents in participants with advanced malignancies who participated in a prior BeiGene sponsored clinical study (parent study).



ACTRN/NCT /ethics:


Scientific title:

An Open-Label, Multicentre, Long-term Extension Study of Tislelizumab-Containing Treatment and/or Pamiparib-Containing Treatment in Patients with Advanced Malignancies

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2019-01-19
Anticipated End Date2024-12-16

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Phone08 8222 6140
Principal InvestigatorDr Amanda Townsend
Recruitment StatusRecruiting